ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.480,89
0,21%
S&P 500
5.187,67
0,00%
US Dollar vs BRL
5,0892
0,00%
Bitcoin
61.500,86
0,51%
Brent Oil
83,75
0,23%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Notícias

ABUS

Arbutus Biopharma (ABUS)

Arbutus Biopharma Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABUS
DataHoraFonteTítuloCódigoCompanhia
07/05/202408:30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202408:30GlobeNewswire Inc.Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202408:25GlobeNewswire Inc.Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024NASDAQ:ABUSArbutus Biopharma Corporation
18/04/202408:30GlobeNewswire Inc.Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/04/202409:30GlobeNewswire Inc.Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
05/03/202418:48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
29/02/202409:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
29/02/202409:30GlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
15/02/202409:30GlobeNewswire Inc.Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
14/02/202418:38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
05/02/202421:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
08/01/202409:30GlobeNewswire Inc.Arbutus Announces 2024 Corporate Objectives and Provides Financial UpdateNASDAQ:ABUSArbutus Biopharma Corporation
21/11/202310:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABUSArbutus Biopharma Corporation
08/11/202309:30GlobeNewswire Inc.Arbutus to Present at Jefferies London Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202318:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
07/11/202309:30GlobeNewswire Inc.Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202309:15GlobeNewswire Inc.Arbutus Announces CEO, William Collier, to Retire December 31, 2023NASDAQ:ABUSArbutus Biopharma Corporation
24/10/202308:30GlobeNewswire Inc.Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
18/10/202308:30GlobeNewswire Inc.Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
11/10/202309:05GlobeNewswire Inc.Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023NASDAQ:ABUSArbutus Biopharma Corporation
11/09/202317:15GlobeNewswire Inc.Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202317:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202308:30GlobeNewswire Inc.Arbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
20/07/202308:30GlobeNewswire Inc.Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
13/07/202317:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
12/07/202308:30GlobeNewswire Inc.Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of DirectorsNASDAQ:ABUSArbutus Biopharma Corporation
10/07/202317:01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:ABUSArbutus Biopharma Corporation
21/06/202308:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ABUSArbutus Biopharma Corporation
21/06/202308:30GlobeNewswire Inc.Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyNASDAQ:ABUSArbutus Biopharma Corporation
21/06/202303:01GlobeNewswire Inc.Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023NASDAQ:ABUSArbutus Biopharma Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABUS

Seu Histórico Recente

BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
IBOV
Índice Bovespa
BOV
VVEO3
CM Hospitalar ON
BOV
JHSF3
JHSF PART ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
SGPS3
SPRINGS ON
BOV
ENAT3
ENAUTA ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PRIO3
PETRORIO ON
BOV
BRKM5
BRASKEM PNA
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados